Fountain Medical Development Co., Ltd.   Report issue

For profit Phase 1
Founded: Beijing China (1995)

Organization Overview

First Clinical Trial
2017
NCT03175497
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Fountain Medical Development Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

ms-553 (1 trial)

telatinib mesylate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetic Retinopathy (Phase 1)

Edema (Phase 1)

Macular Edema (Phase 1)

Neoplasms (Phase 1)

Retinal Diseases (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2